secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2026-08-06T20:03:51+00:00
Accession:  0001628280-26-054273
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q2 revenue $151M (+3% ex-settlements); raises FY2026 guidance to $610-630M
--------------------------------------------------------------------------------

- Revenue $151.0M, up 3% YoY excluding patent settlement revenue; gross margin 74% vs 72%.
- Operating loss $19.6M vs prior-year operating income $30.1M; net loss $17.9M vs net income $34.5M.
- Acquired Proteintech Genomics for protein detection; collaborations with Cleveland Clinic and Lausanne University Hospital.
- Raises FY2026 revenue guidance to $610-630M from $600-625M, representing 2-5% growth ex-settlements.
- Cash and marketable securities $552.0M as of June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000162828026054273/0001628280-26-054273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000162828026054273/txg-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-054273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer